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pretreatment. But we also found that isoAb42 retains a slight aggregative nature, which is signiﬁcantly
weaker than that of the native Ab42.
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Alzheimer’s disease (AD)-related amyloid b peptide (Ab)1–3 is a
highly aggregative peptide. This property hampers not only its
chemical synthesis but also its biological evaluations. Among Ab
species, Ab1–42 (Ab42) is especially difﬁcult to handle although
its aggregative state is thought to be important for the AD progres-
sion.4,5 Thus far, despite intensive efforts, the molecular level
mechanisms of the toxicity of Ab42 remain unclear. This is in part
because of the uncontrollable aggregative nature of Ab42: it forms
aggregates even under usual storage conditions, for example,
DMSO.6 Thus, when a researcher wants to use a monomeric Ab42
or a size-controlled oligomer, pretreatment for disaggregation
must be done. Against this background, many disaggregative
pretreatments have been reported.7–9 In most of them, Ab42 is ﬁrst
dissolved in organic solvents (e.g., DMSO or HFIP) to disaggregate
it. The organic solvent is then removed by evaporation or chro-
matographic separation to afford monomeric Ab42. Unfortunately,
these procedures lower reproducibility and complicate inter-
laboratory discussions.7,8,10–12 Also, any residual organic solventmay affect the subsequent assays.13,14 Moreover, the obtained
monomeric Ab may regenerate aggregates because of its inherent
aggregative nature. To overcome these obstacles, an ‘O-acyl isopep-
tide method’ was tried in 2004.15–17
We had originally developed the O-acyl isopeptide method for
the preparation of peptides with synthetic difﬁculties.18,19 In this
method, an O-acyl isopeptide is chemically synthesized as a pre-
cursor molecule. The O-acyl isopeptide contains an O-acyl isopep-
tide bond instead of the native N-acyl peptide bond at a hydroxyl
group-containing amino acid residue, for example, Ser or Thr.
Incorporation of the isopeptide structure disrupts the undesired
secondary structure formation such as b-sheets. The target peptide
can be quantitatively obtained by a quick O-to-N intramolecular
acyl migration reaction under neutral conditions. The method
has been successfully applied to many amyloidogenic peptides.
In the case of Ab42, an isopeptide of Ab42 (isoAb42) containing
the O-acyl isopeptide bond between Gly25-Ser26 was designed
and synthesized (Scheme 1). When isoAb42 is dissolved under
neutral conditions, a quick O-to-N intramolecular acyl migration
reaction quantitatively generates the native Ab42. Additionally,
monomeric isoAb42 obtained after pretreatment retains the
Table 1
Scheme 1. Aggregative Ab42 (2) was released from the less aggregative isoAb42 (1) through the spontaneous O-to-N intramolecular acyl migration reaction in neutral
condition. Generally, the half time of this migration reaction is ca. 10 s under physiological conditions.20
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Ab42. This is because incorporation of the isopeptide structure
effectively disrupts the aggregation-prone secondary structure of
the native peptide.20 As a result, isoAb42 was regarded as a stable
non-aggregative precursor molecule for Ab42, and monomeric
Ab42 could be readily obtained on demand after the O-to-N
intramolecular acyl migration reaction under neutral conditions
(a so-called click peptide methodology).21 Many researchers have
applied it to biological or biophysical assays, however, isoAb42 is
applied after pretreatments in a similar manner to the native
Ab42.22–27 This is partly because the aggregation state of isoAb42
without pretreatment is not yet clearly understood. Here we report
for the ﬁrst time the concentration-dependent aggregative state of
isoAb42 without pretreatment by analytical ultracentrifugation
and CD spectra. Even though no pretreatment was applied, isoAb42
was conﬁrmed as a monomeric and random coil structure at
40 lM, while larger aggregates were observed at 140/500 lM.
First, we conﬁrmed stability of isoAb42 (1)28 in 0.1% TFA aq. This
acidic condition (pH ca. 2) is appropriate for keeping isoAb42 in
solution. Stability under this condition is also important for the sub-
sequent analyses. As shown in Figure 1, isoAb42 was sufﬁciently
stable although slight degradation (ca. 1%) associated with ester
hydrolysis was observed over 24 h at room temperature [purity
of 1 was 97% (0 h) and 95% (24 h)]. In particular, no migration
reaction to produce the native Ab42 peptide was observed under
this condition. These results suggested that the amino group of
the isopeptide structure is effectively protected as an ammonium
form under the acidic conditions.
We then carried out sedimentation equilibrium analytical ultra-
centrifugation (SE-AUC) experiments to determine the aggregative
state of isoAb42 (1) under acidic conditions. Using SE-AUC, theFigure 1. Ester hydrolysis of isoAb42 (1) in 0.1% TFA aq at room temperature.weight-average molecular weight of complexes in solution can
be directly measured. This feature is a unique property of
SE-AUC. The results are summarized in Table 1, and records of
the experiments are presented in Figures 2 and S1,2. We conﬁrmed
monomeric Mapp (4.8 kDa) at 40 lM in 0.1% TFA aq (Fig. 2AB and
Table 1, Entry 1). After the solution had been stored for 2 weeks
at 80 C, similar monomeric Mapp (4.5 kDa) was still observed
(Table 1, Entry 2). Even in HCl (14 mM) aq solution of isoAb42
(HCl form, 40 lM), similar monomericMapp (4.5 kDa) was observed
(Table 1, Entry 5). On the other hand, higher Mapp values were
observed in 140/500 lM isopeptide solutions in 0.1% TFA aq
(223 kDa for 140 lM/329 kDa for 500 lM) (Table 1, Entries 3, 4,
Figs. 2C, S2). As a control experiment, we applied native Ab42
(40 lM in 0.1% TFA aq) to SE-AUC. As native Ab42 forms aggregate
too strongly, Mapp value of the aggregate was roughly estimated as
1700 kDa (Table 1, Entry 6, Fig. 2D). Additionally, to evaluate the
association of the isoAb42 molecules we performed sedimentation
velocity analytical ultracentrifugation (SV-AUC) at 40 lM solution
in 0.1% TFA aq. The polydispersity of the solute can be monitored as
a function of sedimentation coefﬁcients using the size-distribution
analysis based on SV-AUC data. As shown in Figure 3, the distribu-
tion proﬁle was obviously monodisperse. The major component of
which apparent sedimentation coefﬁcient was 0.4 S accounted for
more than 96%. The molecular weight determined by SE-AUC must
reﬂect molecular weight of this major component which
corresponds to the isopeptide monomer. Based on these results
of SE-/SV-AUC, we concluded that isoAb42 in 40 lM solution of
0.1% TFA aq exists as a monomer.Weight-average molecular weight (Mapp) values of isoAb42 (1) under various
conditionsa
Entry Concentration (lM) Counter anion Mapp (kDa)
1 40 TFA 4.8
2b 40 TFA 4.5
3 140 TFA 223
4 500 TFA 329
5 40 HCl 4.7
6c 40 TFA 1700
a Weight-average molecular weight (Mapp) was determined by the analytical
ultracentrifugation using the sedimentation equilibrium method. Theoretical
molecular weight of monomeric isoAb42 is 4.5 kDa. Representative results appear
in Figure 2. For more detail, see Materials and Methods section and Supplemental
Information.
b After storing 40 lM of isoAb42 solution in 0.1% TFA aq at 80 C for 2 weeks.
c Native Ab42 was used instead of isoAb42.
Figure 2. Representative results of sedimentation equilibrium of analytical ultracentrifugation (AUC). The lower ﬁgures show the absorbance versus the distance from the
center of rotation, and the line drawn through the points gives the expected absorbance corresponding to a particular MW. The upper ﬁgures show the residuals calculated
from the actual absorbance values. (A) IsoAb42 (TFA form) was dissolved in 0.1% TFA aq at 40 lM, and analyzed by AUC with a rotating speed of 6000 rpm. Because of the low
MW of solute, deviation after sedimentation equilibrium was not enough to estimate theMapp value under this relatively low gravity condition. (B) Similar experiment to (A)
but with a higher rotating speed (30,000 rpm). Using this appropriate condition for monomeric isoAb42, the Mapp value of isoAb42 at 40 lM was successfully calculated as
4.8 kDa. (C) Similar experiment to (A) but with a higher concentration (140 lM) of isoAb42 (TFA form). In this case, isoAb42 formed large aggregates, so that theMapp value of
the complex of isoAb42 was successfully calculated as 223 kDa even with a rotating speed of 6000 rpm. (D) Similar experiment to (A) but with 40 lM of ‘native’ Ab42 (TFA
form). Under this condition, Ab42 formed much larger aggregates and the Mapp value of the complex of Ab42 was roughly calculated as 1700 kDa.
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centrations (40 lM, 140 lM and 500 lM) in 0.1% TFA aq at 4 C to
monitor the secondary structures (Fig. 4). A random coil structure
was clearly present in a 40 lM solution. By contrast, a b-sheet
structure was observed in a 500 lM solution. In a 140 lM solution,
transient structures between the random coil and the b-sheet
seemed to be present. Additionally, the b-sheet structure formed
at 500 lM was not transformed into a monomeric form by its
dilution to 40 lM (Fig. S3). Similarly, a random coil structure was
observed with a 40 lM solution of isoAb42 (HCl form) in 14 mM
HCl aq (Fig. S4).
Every experiment conducted by SE-/SV-AUC and CD analyses
suggested that isoAb42 adopts a monomeric and random coil
structure at 40 lM in 0.1% TFA aq even though no pretreatment
was applied. The results clearly indicated that monomeric native
Ab42 solution would be readily obtained using a 40 lM stock solu-tion of isoAb42 without the aid of pretreatment. On the other hand,
aggregations of isoAb42 were observed when raising the concen-
tration to 140 and 500 lM. Aggregates which had been once
formed were not disaggregated by diluting the solution. These
results are consistent with those of the Penke group report that
isoAb42 without pretreatment seems to form an aggregate at
500 lM.22 In the case of native Ab42, however, much larger aggre-
gates (ca. 1700 kDa) were formed at 40 lM.
Native Ab42 can be obtained immediately after neutralization
of the acidic stock solution of isoAb42 via the O-to-N acyl migration
reaction. Therefore, to obtain monomeric Ab42 with a random coil
structure the acidic stock solution has to solely consist of mono-
meric isoAb42 with a random coil structure.20,21 The presence of
preformed seeds in the stock solution that can induce peptide
aggregation often results in variability in polymerization kinetics.
Many kinds of pretreatment methods, which had been originally
Figure 3. IsoAb42 (TFA form) was dissolved in 0.1% TFA aq at 40 lM, and applied to
sedimentation velocity analytical ultracentrifugation (SV-AUC) analysis. Inset is an
enlarged view around 0–10 S.
Figure 4. CD spectra of isoAb42 in 0.1% TFA aq.
3864 T. Yoshiya et al. / Bioorg. Med. Chem. Lett. 24 (2014) 3861–3864reported for disaggregation of the native Ab peptides, have been
applied for preparation of the acidic stock solution of monomeric
isoAb42 peptides. For example, in the case of ultracentrifugation
pretreatment,20,29 0.1% TFA aq solution of isoAb42 (280 lM) was
ultra-centrifuged (435,000 or 541,000g) and the upper three-quar-
ters fraction was collected. Then, the peptide concentration was
estimated on the basis of UV absorption. In the case of MW-cutoff
ﬁltration pretreatment, 0.02% TFA aq solution (ca. 200 lM) of
isoAb42 was ﬁltered through a 10-kDa cutoff ﬁlter.23,24 In the case
of HFIP pretreatment, isoAb42 was ﬁrst treated with HFIP over-
night. After removal of HFIP by evaporation, isoAb42 was re-dis-
solved in H2O to afford acidic stock solution.22,25 Such
pretreatments not only lead to low recovery of the peptides but
also result in study outcomes that are irreproducible or discrep-
ant.7–12 Therefore, our non-pretreatment strategy for monomeric
Ab42 should facilitate reproducible biological assays in future
AD-related research.
To our surprise, after exchange of a counter anion from TFA to
HCl, isoAb42 at 40 lM still retained a random and monomeric
structure in 14 mM HCl aq, a condition of similar acidity to 0.1%
TFA aq (the conventional stock condition). Generally, Ab species
are prone to aggregate in the HCl form rather than the TFA
form.30,31 Thus, stock condition for isoAb42 was also thought to
require TFA anion to obtain monomeric Ab42. Judging from our
results, TFA in the stock solution of isoAb42 could be substituted
with HCl. Use of this substitution could enable benign applications
of isoAb42, because TFA is known to sometimes affect cellular
assays or in vivo assays.14,32In summary, we conﬁrmed that isoAb42 without pretreatment
has a monomeric and random coil form under acidic conditions
at 40 lM based on the data from analytical ultracentrifugation
and CD spectra. This nature was not altered by the conversion of
counter anion from TFA to HCl. By contrast, larger aggregates were
observed at higher concentrations. Our non-pretreatment strategy
to obtain monomeric Ab42 with a random coil structure from
isoAb42 should make possible reproducible biological assays for
AD-related research.
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.bmcl.2014.
06.052. These data include MOL ﬁles and InChiKeys of the most
important compounds described in this article.
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